ArticleChinese medicine2026
Integrating network pharmacology, transcriptomics, and experimental validation: Compound Baixianpi Formula targets IL-17A to inhibit dual PI3K-AKT/JAK2-STAT3 pathways for psoriasis improvement.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPsoriasis is an immune-mediated chronic inflammatory skin disease. Existing therapies have limitations, necessitating the development of new treatment approaches. Compound Baixianpi Formula (FFBXP) is a clinically effective topical Chinese herbal formula, but its material basis and mechanism of action remain unclear. MATERIALS AND
methodsFFBXP components were identified using UHPLC-Q-Orbitrap HRMS. Core targets and pathways were screened by integrating network pharmacology and transcriptomics analyses. The effects of FFBXP on skin lesions, histopathology, oxidative stress, and inflammatory mediators (IL-17A, IL-23, TNF-α) were evaluated using a IMQ mouse psoriasis model and a TNF-α-stimulated HaCaT cell model. Key mechanisms were validated through molecular docking, qRT-PCR, Western blot, and immunofluorescence techniques.
resultsForty-two active components were identified in FFBXP. In vivo experiments demonstrated that FFBXP significantly improved erythema and skin lesion infiltration in psoriatic mice, while reducing levels of inflammatory cytokines (IL-17A, IL-23, TNF-α) and oxidative stress markers (MDA). In vitro experiments confirmed that FFBXP dose-dependently inhibited TNF-α-induced proliferation in HaCaT cells, reduced inflammatory cytokine levels, mitigated oxidative stress, and promoted apoptosis. Network pharmacology and transcriptomics analysis indicated its mechanism involves IL-17, PI3K-AKT, and JAK2-STAT3 signaling pathways. Molecular docking showed that six core active ingredients (berberine, resveratrol, quercetin, catechin, kaempferol, and osthol) had good binding activity with key target proteins. Further mechanism validation revealed FFBXP significantly decrease IL-17A expression and inhibited phosphorylation of downstream PI3K, AKT, JAK2, and STAT3 proteins.
conclusionThis study employs a combined strategy of network pharmacology, transcriptomics, and experimental validation to elucidate for the first time that FFBXP exerts its anti-psoriasis effects by targeting IL-17A and collaboratively inhibiting two key signaling pathways: PI3K-AKT and JAK2-STAT3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.